Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 66

1.

Raltegravir-induced cerebellar ataxia.

Reiss KA, Bailey JR, Pham PA, Gallant JE.

AIDS. 2010 Nov 13;24(17):2757. doi: 10.1097/QAD.0b013e32833fca42. No abstract available.

PMID:
20980871
2.

Etravirine-raltegravir, a marked interaction in HIV-1-infected patients: about four cases.

Ménard A, Solas C, Mokthari S, Bregigeon S, Drogoul MP, Tamalet C, Lacarelle B, Martin IP.

AIDS. 2009 Apr 27;23(7):869-71. doi: 10.1097/QAD.0b013e328329915f. No abstract available.

PMID:
19363331
3.

Short communication: high effectiveness of etravirine in routine clinical practice in treatment-experienced HIV type 1-infected patients.

Santos JR, Llibre JM, Domingo P, Imaz A, Ferrer E, Podzamczer D, Bravo I, Ribera E, Videla S, Clotet B.

AIDS Res Hum Retroviruses. 2011 Jul;27(7):713-7. doi: 10.1089/AID.2010.0283. Epub 2011 Jan 15.

PMID:
21114458
4.

HIV RNA suppression rates after 24 weeks of treatment with etravirine, darunavir/ritonavir and raltegravir in the etravirine early access programme.

Florence E, De Wit S, Castagna A, Ribera E, Hill A, Vanaken H, van Delft Y, Marks S.

Int J STD AIDS. 2010 Mar;21(3):224-5. doi: 10.1258/ijsa.2009.009425. Epub 2010 Jan 13. No abstract available.

PMID:
20071441
5.

Reply to 'Pharmacokinetics of etravirine, raltegravir and darunavir/ritonavir in treatment experienced patients'.

Cattaneo D, Gervasoni C.

AIDS. 2011 Apr 24;25(7):1012-3; author reply 1011-2. doi: 10.1097/QAD.0b013e3283463c84. No abstract available.

PMID:
21412129
6.

Severe insomnia related to high concentrations of raltegravir.

Eiden C, Peyriere H, Peytavin G, Reynes J.

AIDS. 2011 Mar 13;25(5):725-7. doi: 10.1097/QAD.0b013e32834465c8. No abstract available.

PMID:
21368594
7.

Elevated alkaline phosphatase with raltegravir in a treatment experienced HIV patient.

Fleischbein E, O'Brien J, Martelino R, Fenstersheib M.

AIDS. 2008 Nov 12;22(17):2404-5. doi: 10.1097/QAD.0b013e328316eb91. Review. No abstract available.

PMID:
18981785
8.

Sustained efficacy and safety of raltegravir after 5 years of combination antiretroviral therapy as initial treatment of HIV-1 infection: final results of a randomized, controlled, phase II study (Protocol 004).

Gotuzzo E, Markowitz M, Ratanasuwan W, Smith G, Prada G, Morales-Ramirez JO, Strohmaier KM, Lu C, Bhanja S, Nguyen BY, Teppler H; Protocol 004 Study Team.

J Acquir Immune Defic Syndr. 2012 Sep 1;61(1):73-7.

PMID:
22743596
9.

[Integrase inhibitor: raltegravir also as first line therapy].

[No authors listed]

MMW Fortschr Med. 2010 Apr 29;152(17):48. German. No abstract available.

PMID:
20509261
10.

Use of newer antiretroviral agents, darunavir and etravirine with or without raltegravir, in pregnancy: a report of two cases.

Jaworsky D, Thompson C, Yudin MH, Bitnun A, Brophy J, Samson L, Antoniou T, Loutfy MR.

Antivir Ther. 2010;15(4):677-80. doi: 10.3851/IMP1558.

PMID:
20587860
11.

Long-term efficacy and safety of raltegravir, etravirine, and darunavir/ritonavir in treatment-experienced patients: week 96 results from the ANRS 139 TRIO trial.

Fagard C, Colin C, Charpentier C, Rami A, Jacomet C, Yeni P, Vittecoq D, Katlama C, Molina JM, Descamps D, Chêne G, Yazdanpanah Y; ANRS 139 TRIO Trial Group.

J Acquir Immune Defic Syndr. 2012 Apr 15;59(5):489-93. doi: 10.1097/QAI.0b013e31824bb720.

PMID:
22293546
12.

Severe dyslipidaemia after the addition of raltegravir to a lopinavir/ritonavir-containing regimen.

Huesgen E, Burgos R, Goldstein DA, Max B, Jarrett OD.

Antivir Ther. 2012;17(7):1385-8. doi: 10.3851/IMP2182. Epub 2012 Jun 22.

PMID:
22728657
13.

Cost-effectiveness of raltegravir in HIV/AIDS.

Chaudhary MA, Elbasha EH, Kumar RN, Nathanson EC.

Expert Rev Pharmacoecon Outcomes Res. 2011 Dec;11(6):627-39. doi: 10.1586/erp.11.79. Review.

PMID:
22098278
14.

Efficacy, safety, and tolerability of etravirine with and without darunavir/ritonavir or raltegravir in treatment-experienced patients: analysis of the etravirine early access program in the United States.

Towner W, Lalezari J, Sension MG, Wohlfeiler M, Gathe J, Appelbaum JS, Bellman P, Gottlieb MS, Ryan R, Nijs S, Hoogstoel A, Van Solingen-Ristea R, Witek J.

J Acquir Immune Defic Syndr. 2010 Apr;53(5):614-8. doi: 10.1097/QAI.0b013e3181cdebb1.

PMID:
20134329
15.

Minimal pharmacokinetic interaction between the human immunodeficiency virus nonnucleoside reverse transcriptase inhibitor etravirine and the integrase inhibitor raltegravir in healthy subjects.

Anderson MS, Kakuda TN, Hanley W, Miller J, Kost JT, Stoltz R, Wenning LA, Stone JA, Hoetelmans RM, Wagner JA, Iwamoto M.

Antimicrob Agents Chemother. 2008 Dec;52(12):4228-32. doi: 10.1128/AAC.00487-08. Epub 2008 Oct 6.

16.

Raltegravir-induced DRESS syndrome.

Loulergue P, Mir O.

Scand J Infect Dis. 2012 Oct;44(10):802-3. Epub 2012 Jul 17.

PMID:
22803794
17.

Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study.

Martínez E, Larrousse M, Llibre JM, Gutiérrez F, Saumoy M, Antela A, Knobel H, Murillas J, Berenguer J, Pich J, Pérez I, Gatell JM; SPIRAL Study Group.

AIDS. 2010 Jul 17;24(11):1697-707. doi: 10.1097/QAD.0b013e32833a608a. Erratum in: AIDS. 2010 Oct 23;24(16):2602.

PMID:
20467288
18.

A case of rhabdomiolysis associated with raltegravir use.

Dori L, Buonomini AR, Viscione M, Sarmati L, Andreoni M.

AIDS. 2010 Jan 28;24(3):473-5. doi: 10.1097/QAD.0b013e328334cc4a. No abstract available.

PMID:
20087078
19.

Long-term efficacy and safety of the HIV integrase inhibitor raltegravir in patients with limited treatment options in a Phase II study.

Gatell JM, Katlama C, Grinsztejn B, Eron JJ, Lazzarin A, Vittecoq D, Gonzalez CJ, Danovich RM, Wan H, Zhao J, Meibohm AR, Strohmaier KM, Harvey CM, Isaacs RD, Nguyen BY; Protocol 005 Team.

J Acquir Immune Defic Syndr. 2010 Apr 1;53(4):456-63.

PMID:
20306554
20.

Liver tolerance of raltegravir-containing antiretroviral therapy in HIV-infected patients with chronic hepatitis C.

Macías J, Neukam K, Portilla J, Iribarren JA, de Los Santos I, Rivero A, Márquez M, Delgado M, Téllez F, Merino D, Giner L, von Wichmann MA, Pineda JA; HEPRAL study team.

J Antimicrob Chemother. 2011 Jun;66(6):1346-50. doi: 10.1093/jac/dkr083. Epub 2011 Mar 10.

PMID:
21398295

Supplemental Content

Support Center